Monthly Updates: Central and Peripheral Nervous System: What makes atypical antipsychotics atypical? The case for serotonergic mechanism of action

References

• JANSSEN PAJ, NIEMERGEERS CJE, AWOUTERS FHL, SCHELLEKENS AH, MEGENS AAHP, MEERT TF: Pharmacol-ogy of risperidone (R64 766), anew antipsychotic with serotonin-S2 and dopamine 1)2 antagonistic properties. J. Pharmacol. K. Ther. (1988) 244:685–693.
   PubMed Web of Science ®Google Scholar
• A complete preclinical profile of risperidone.
   Google Scholar
• MARDER SR, MEIBACH RC: Risperidc in the treatment of schizophrenia. Am. J. Psychiat. (1993) 151:825–835.
   Web of Science ®Google Scholar
• MEGENS AAHP, AWOUTERS FHL, SCHOTTE A, MEERT TF, NLEMEGEERS CJE, LEYSEN JE: Survery on the pharma-codynamics of the new antipsychotic risperidone. Psy-chopharmacology (1994) 114:9–23.
   PubMed Web of Science ®Google Scholar
• HEINRICH K, KLEISER E, LEHMANN E, KINZLER E, HRUSCHKA H: Risperidone versus clozapine in the treat-ment of schizophrenic patients with acute symptoms:
   Google Scholar
• A double-blind randomised trial. NeuroPsychopharmacol and Biol. Psychiat. (1994) 18:129–137.
   Google Scholar
• Small comparative study investigating possible differences between the only two atypical antipsychotics currently in clinical use.
   Google Scholar
• MOORE N, TUPPER DE, HO! 11EN TM: Olanzepine. Drugs Future (1994) 19:114–117.
   Google Scholar
• TOLLEFSON GD: Olanzepine: A novel antipsychotic with a broad spectrum profile. Neuropsychopharmacology (1994) 10:805S.
   Google Scholar
• BEASLEY CM, TOLLEFSON GC, MOORE N, TYE N: (Ban- zepine: the new 'atypical' antipsychotic agent Neurop-sychopharmacology (1994) 10:536S.
   Google Scholar
• HIRSCH SR: Seroquel: An example of an atypical antip-sychotic drug. Neuropsychopharmacology(1994) 10:371S.
   Google Scholar
• DE BOER T, BERENSEN H, BROEICKAMP CLE, VRIJMOED-DE VRIES MC, TONNEAR JADM, DELFT AML: Org-5222. Drugs Future (1993) 18:1117–1123.
   Google Scholar
• A full pre-clinical profile of this compound.
   Google Scholar
• SEEGER TF, SCHMIDT AW, LEBEL LA, KOE BK, ZORN SH,SCHULZ DW, HOWARD HR, HEYM JH: CP88,059: a new antipsychotic with mixed dopamine 132 and serotonin 5-HT2 antagonist activities. Soc. Neurosci. Abs (1993) 661:1.
   Google Scholar
• SEYMOUR PA, SEEGER TF, GUANOWSKY V, ROBINSONGL, HOWARD H, HEYM J: Behavioural pharmacology of CP-88,059: Anew antipsychotic with both 5-HT2 and 132 antagonist activities. Soc. Neurosci. Abs. (1993) 246:20.
   Google Scholar
• REITZ AB, BENNETT DJ, BLUM PA, CODD EE, MARYANOFFCA, ORTEGON ME, RENZI MJ, SCOTT MK, SHANK RP, VAUGHT JL: A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/a1A-adrenergic affinity and a low potential for extrapyramidal effects. J. Med. Chem.(1994) 37:1060–1062.
   PubMed Web of Science ®Google Scholar
• SHAPIRO ET AL.: Effect of chronic treatment with the novel antipsychotic RWJ-37796 on D1 and D2 dopamine receptors in rat brain. Soc. Neurosci. Abs. (1993) 246:14.
   Google Scholar
• WIESEL F-A, NORDTROM A-L, FARDE L, ERIKSSON B: An open clinical trial and biochemical study of ritanserin In acute patients with schizophrenia. Psychopharmacol-ogy (1994) 114:31–38.
   PubMed Web of Science ®Google Scholar
• An open study in a small number of patients which strongly suggests that 5-HT2 blockade ameliorates psychotic symptoms.
   Google Scholar
• ARNT J, SANCHEZ C, SKARSFELDT T: The so-called atypi- cal antipsychotics. How similar are they? Neuropsycho-pharmacology (1994) 10:469S.
   Google Scholar
• Abstract comparing behavioural profiles of a range of atypical antipsychotics.
   Google Scholar
• MELTZER HY: The importance of serotonin-dopamine interactions in the action of clozapine. Br. J. Psychiatry (1992) 160\(Suppl. 17):22–29.
   Google Scholar
• Article from a supplement dedicated entirely to clozapine. A sum-mary of the evidence linking clinical efficacy of clozapine to action at serotonergic receptors.
   Google Scholar
• LEYSEN JE, MEGENS AAHP, JANSSEN PAJ, SCHO'rT A: Finely balanced 5-11T2/D2 antagonism: A crucial factor for the treatment of schizophrenia. Neuropsychopharma-cology (1994) 10:467S.
   Google Scholar
• BROUGHAM LR, CONWAY PG, ELLIS DB: Effect of ritan-serin on the interaction of amfolenic acid and neurolep-tic-induced striatal dopamine metabolism. Neuropharmacology (1991) 30:1137–1140.
   PubMed Web of Science ®Google Scholar
• SCHOTTE A, JANSSEN PAJ, MEGENS AAHP, LEYSEN JE: Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Research (1993) 631:191–202.
   PubMed Web of Science ®Google Scholar
• Comparative study using ex vivo autoradiography to compare occu-pancy of various antipsychotics.
   Google Scholar
• HOYER D, CLARKE DE, FOZARD JR, HARTIG PR, MARTIN GR, MYLECHARANE EJ, SAXENA PR, HUMPHREY PPA: International union of pharmacology classification of receptors for 5-Hydroxytryptamine (serotonin). Phar-macological Reviews (1994) 46:157–203.
   PubMed Web of Science ®Google Scholar
• All you ever wanted to know about serotonin but were afraid to ask.
   Google Scholar
• KENNETT GA: 5-HT1C receptors and their therapeutic relevance. Curr. Opin. Invest. Drugs (1993) 2:317-362. Exhaustive review of 5-HT1C receptor function, whose relevance will not be diminished by recent receptor re-classification.
   Google Scholar
• SCHRIEBER R, BROCCO M, MILLAN MJ: Blockade of the discriminative stimulus effects of DOI by Min 100.97 and the 'atypical' antipsychotics, clozapine and risperi-done. Eur. J. Pharmacol. (1994) 264:99–102.
   Google Scholar
• SORENSEN SM, KEHNE JH, FADAYEL GM, HUMPHREYS TM, KE I ILLER HL, SULLIVAN CK, TAYLOR VL, SCHIMIDT CJ: Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behav-ioural, electrophysiocological and neuorochemical studies. J. Pharmac. Exp. Ther. (1993) 266:684–691.
   PubMedGoogle Scholar
• WADENBERG M-L: Antagonism by 8-0HDPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat./ Neural Transm. (1992) 89:49–59.
   PubMed Web of Science ®Google Scholar
• CORBETI' R, HARTMAN H, ICERMAN LL, WOODS AT, STTRUPEZEWSKI JT, HELSLEY GC, CONWAY PC, DUNN RW: The effects of atypical antipsychotic agents on social behaviour in rodents. Pharmacol. Biochem. Behav. (1993) 45:9–17.
   PubMed Web of Science ®Google Scholar
• One of several possible indicators that atypical antipsychotics have behavioural effects that may differ markedly from their typical counterparts.
   Google Scholar
• SARTER M: Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia; two sides of the same coin? Psychopharmacology (1994) 114:539–550.
   PubMed Web of Science ®Google Scholar
• A thought-provoking review of cholinergic aspects of two psychiatric disorders which argues for a continuum of attentional disorder from dementia to schizophrenia.
   Google Scholar
• VAN TOL TIMM, BUNZOW JR, GUAN HC, SUNAHARA RIC, SEEMAN P, NIZNIK HB, CIVELLI O: Cloning of the gene for a human 04 xreceptor with high affinity for the antipsychotic clozapine. Nature (1991) 350:610–614.
   PubMed Web of Science ®Google Scholar
• SEEMAN P, GUAN H-C, VAN TOL H-HM: Dopamine 04 receptors elevated in schizophrenia. Nature (1993) 365:441-445. (See also News and Views item by Iversen LL p393, same issue.)
   Google Scholar
• FIBIGER HC, GUO NN: Neurochemical substrates of clozapine-induces cps expression in the forebrain. Neuropsychopharmacology (1994) 10:470S.
   Google Scholar
• Abstract of a study which may be crucial to understanding regional differences in the effects of clozapine in the brain.
   Google Scholar
• CRAIG° S, MONSMA FJ, Jr, SHEN Y, MELTZER HY, SIBLEY DR, ROTH BL: Clozapine and selected atypical antipsy-chotic agents have high affinities for the 5-1IT6 and 5-HT7 serotonin receptors. Soc . Neurosci. Abs. (1993) 93:7.
   Google Scholar
• SCHOEFFTER P, WAEBER C: 5-Hydroxylryptamine recep- tors with a 5-HT6 receptor-like profile stimulating adenyly1 cyclase in pig caudate membranes. Nauyn-Schiedeberg's Arch. Pharmacol. (1994) 350:356-360. Possible candidate for 'wild-type' 5-HT6 receptor.
   Google Scholar
• STRANGE PG: Dopamine 04 receptors: Curiouser and curiouser. nps (1994) 15:317–319.
   Web of Science ®Google Scholar
• Update on latest findings on molecular pharmacology of D4 recep-tors.
   Google Scholar